Skip to main content
SpringerLink
Log in

Adjuvant Therapy for Colorectal Cancer

  • Reference work entry
The ASCRS Textbook of Colon and Rectal Surgery

  • 1651 Accesses

Abstract

The stage of disease at presentation remains the most important prognostic factor for colon cancer patients. Stage I disease carries an excellent prognosis of more than 95% 5-year survival rate, and surgical treatment alone is considered sufficient; adjuvant treatment is not indicated. In contrast, adjuvant treatment has repeatedly been shown to improve survival for Stage III disease. The role of adjuvant treatment for Stage II (node-negative) disease remains controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Jemal A, Thomas A, Murray T, et al 2002;Cancer statistics, 2002. CA Cancer J Clin 52:23–47.

    Article  Google Scholar 

  2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. JNCCN 2003;1:40–53.

    Google Scholar 

  3. Wolmark N, Fisher B, Rockette H, et al 1988;Postoperative adjuvant chemotherapy or BCG for colon cancer: results from the NSABP protocol C‐01. J Natl Cancer Inst 80:30–36.

    Article  CAS  Google Scholar 

  4. Laurie JA, Moertel CG, FlemingTR, et al 1989;Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447–1456.

    CAS  Google Scholar 

  5. Moertel CG, Fleming TR, Macdonald JS, et al 1990;Levamisole and 5‐fluorouracil for adjuvant therapy of resected colon cancer. N Engl J Med 322:352–358.

    Article  CAS  Google Scholar 

  6. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444–1450.

    Google Scholar 

  7. Taal BG, Van Tinteren H, Zoetmulder FA, et al 2001;Adjuvant 5‐FU plus levamisole in colonic or rectal cancer: improved survival in stage II or III. Br J Cancer 85:1437–1443.

    Article  CAS  Google Scholar 

  8. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators: efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939–944.

    Google Scholar 

  9. Wolmark N, Rockette H, Fisher B, et al 1993;The benefit of leucovorin‐modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer. Results form National Surgical Adjuvant Breast and Bowel Project protocol CO‐3. J Clin Oncol 11:1879–1887.

    CAS  Google Scholar 

  10. O'Connell MJ, Laurie JA, Kahn M, et al 1998;Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high‐risk colon cancer. J Clin Oncol 16:295–300.

    Google Scholar 

  11. Haller DG, Catalano PJ, Mac DonaldJS, et al 1998;Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five‐year final report of INT‐0089 [abstract]. Proc Am Soc Clin Oncol 17:256.

    Google Scholar 

  12. Wolmark N, Rockette H, Mamounas E, et al 1999;Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project CO‐4. J Clin Oncol 17:3553–3559.

    CAS  Google Scholar 

  13. QUASAR Collaborative Group: comparison of fluorouracil with additional levamisole, higher dose leucovorin or both as adjuvant chemotherapy for colorectal cancer—a randomized trial. Lancet 2000;355:1588–1596.

    Google Scholar 

  14. Topham C, Boni C, Navarro M, et al 2003;Multicenter international randomized study of oxaliplatin/5FU/LV (FOLFOX) in stage II and III colon cancer (MOSAIC trial): final results. Eur J Cancer 1(suppl 5):S324–325. Abstr 1085.

    Google Scholar 

  15. Fallik D, Borrini F, Boige V, et al 2003;Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 15: 5738–5744.

    Google Scholar 

  16. Barratt PL, Seymour MT, Stenning SP, et al 2002;DNA markers predicting benefit from adjuvant fluorouracil in patients with colorectal cancer: a molecular study. Lancet 360:1381–1391.

    Article  CAS  Google Scholar 

  17. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators: efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356–1363.

    Google Scholar 

  18. Schrag D, Gelfand S, Bach P, et al 2001;Adjuvant chemotherapy for stage II colon cancer: insight from a SEER‐Medicare cohort [abstract]. Proc Am Soc Clin Oncol 20:488.

    Google Scholar 

  19. Mamounas E, Wieand S, Wolmark N, et al 1999;Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Projects adjuvant studies (CO‐1, CO‐2, CO‐3 and CO‐4). J Clin Oncol 17:1349–1355.

    CAS  Google Scholar 

  20. Buyse M, Piedbois P. 2001;Should Dukes’ B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28(suppl 1):20–24.

    Article  CAS  Google Scholar 

  21. Krook JE, Moertel CG, Gunderson LL, et al 1991;Effective surgical adjuvant therapy for high‐risk rectal carcinoma. N Engl J Med 324:709–715.

    Article  CAS  Google Scholar 

  22. Willett CG, Tepper JE, Cohen A, et al 1984;Local failure following curative resection of colonic adenocarcinoma. Int J Radiat Oncol Biol Phys 10:645–651.

    Article  CAS  Google Scholar 

  23. Gunderson LL, Sosin H, Levitt S. 1985;Extrapelvic colon‐areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 11:731–741.

    Article  CAS  Google Scholar 

  24. Willett CG, Fung CY, Kaufman DS, et al 1993;Postoperative radiation therapy for high‐risk colon carcinoma. J Clin Oncol 11: 1112–1117.

    CAS  Google Scholar 

  25. Schild SE, Gunderson LL, Haddock MG, et al 1997;The treatment of locally advanced colon cancer. Int J Radiat Oncol Biol Phys 37:51–58.

    Article  CAS  Google Scholar 

  26. Amos EH, Mendenhall WM, McCarty PJ, et al 1996;Postoperative radiotherapy for locally advanced colon cancer. Ann Surg Oncol 3:431–436.

    Article  CAS  Google Scholar 

  27. Martenson J, Willett CG, Sargent D, et al. A phase III study of adjuvant radiation therapy (RT), 5‐fluorouracil (5‐FU), and levamisole (LEV) vs. 5‐FU and LEV in selected patients with resected, high‐risk colon cancer: initial results of INT 0130 [abstract]. Proc Am Soc Clin Oncol 1999;18:235.

    Google Scholar 

  28. Hanna MG Jr, Hoover HC Jr, Vermoken JB, et al. 2001;Adjuvant active specific immunotherapy of stage II and stage III colon cancer with autologous tumor cell vaccine: First randomized phase III trials show promise. Vaccine 19:2576–2582.

    Article  Google Scholar 

  29. Hoover HC Jr, Brandhorst JS, Peters LC, et al 1993;Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow‐up of a phase III prospectively randomized trial. J Clin Oncol 11:390–399.

    Google Scholar 

  30. Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and II colon cancer autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5238. J Clin Oncol 2000;18:148–157.

    CAS  Google Scholar 

  31. Vermoken JB, Claessen AM, Van Tinteren H, et al 1999;Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353:345–350.

    Article  Google Scholar 

  32. Camma C, Giunta M, Fiorica F, et al 2000;Preoperative radiotherapy for resectable rectal cancer: a meta‐analysis. JAMA 284: 1008–1015.

    Article  CAS  Google Scholar 

  33. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358:1291–304.

    Google Scholar 

  34. Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin‐Ståhl E. 2003;A systematic overview of radiation therapy in rectal cancer. Acta Oncol 42:476–492.

    Article  Google Scholar 

  35. Påhlman L, Glimelius B. 1990;Pre‐ or postoperative radiotherapy in rectal and rectosigmoid carcinoma: report from a randomized multicentre trial. Ann Surg 211:187–195.

    Article  Google Scholar 

  36. Roh MS, Petrilli N, Wieand H, et al 2001;Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R‐03) [abstract]. Proc Am Soc Clin Oncol 20:123a.

    Google Scholar 

  37. Sauer R, Fietkau R, Wittekind C, et al 2001;Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. Strahlenther Onkol 177:173–181.

    Article  CAS  Google Scholar 

  38. Garcia‐Aguilar J, Pollack J, Lee SH, et al 2002;Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. Dis Colon Rectum 45:10–15.

    Article  Google Scholar 

  39. Beets‐Tan RGH, Beets GL, Vliegen RFA, et al 2001;Accuracy of magnetic resonance imaging in prediction of tumour‐free resection margin in rectal cancer surgery. Lancet 357:497–504.

    Article  Google Scholar 

  40. Swedish Rectal Cancer Trial: initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Br J Surg 1993;80:1333–1336.

    Google Scholar 

  41. Heald RJ, Karanjia ND. 1992;Results of radical surgery for rectal cancer. World J Surg 16:848–857.

    Article  CAS  Google Scholar 

  42. Enker WE. 1992;Potency, cure, and local control in the operative treatment of rectal cancer. Arch Surg 127:1396–1401.

    CAS  Google Scholar 

  43. Moriya Y, Hojo K, Sawada T, Koyama Y. 1989;Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection. Dis Colon Rectum 32:307–315.

    Article  CAS  Google Scholar 

  44. Wibe A, Rendedal PR, Svensson E, et al 2002;Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 89:327.

    Article  CAS  Google Scholar 

  45. Dahlberg M, Glimelius B, Påhlman L. 1999;Changing strategy for rectal cancer is associated with improved outcome. Br J Surg 86:379–84.

    Article  CAS  Google Scholar 

  46. Martling AL, Holm T, et al 2000;Effect of a surgical training programme on the outcome of rectal cancer in the County of Stockholm. Lancet 356:93–96.

    Article  CAS  Google Scholar 

  47. Swedish Rectal Cancer Register. Available at: http://www.SOS.se/mars/kvaflik.htm (Swe).

  48. Kapiteijn E, Matijnen CA, Naggtegaal ID, et al 2001;Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646.

    Article  CAS  Google Scholar 

  49. Bosset JF, Pierat M, Van Glabbeke M. 2000;Preoperative radiochemotherapy versus preoperative radiotherapy with or without postoperative chemotherapy: progress report of the EORTC 22921 trial [abstract]. Radiother Oncol 56:S52.

    Google Scholar 

  50. Fisher B, Wolmark N, Rockette H, et al 1988;Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer. Results from NSABP protocol R‐01. J Natl Cancer Inst 80:21–29.

    Article  CAS  Google Scholar 

  51. Wolmark N, Weiand HS, Hyams DM, et al 2000;Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project protocol R‐02. J Natl Cancer Inst 92:388–396.

    Article  CAS  Google Scholar 

  52. Willett CG, Tepper JE, Kaufman DS, et al 1992;Adjuvant postoperative radiation therapy for rectal adenocarcinoma. Am J Clin Oncol 15:371–375.

    Article  CAS  Google Scholar 

  53. Krook JE, Moertel CG, Gunderson LL, et al 1991;Effective surgical adjuvant therapy for high‐risk rectal carcinoma. N Engl J Med 324:709–715.

    Article  CAS  Google Scholar 

  54. Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer: results of a prospective randomized trial. N Engl J Med 1984;310:737–743.

    Google Scholar 

  55. National Institutes of Health Consensus Conference: adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444–1450.

    Google Scholar 

  56. Tveit KM, Guldvog I, Hagen S, et al 1997;Randomised controlled trial of postoperative radiotherapy and short‐term time‐scheduled 5‐fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Br J Surg 84:1130–1135.

    Article  CAS  Google Scholar 

  57. Påhlman L, Enblad P, Glimelius B. 1985;Clinical characteristics and their relation to surgical curability in adenocarcinoma of the rectum and recto‐sigmoid: a population‐based study in 279 consecutive patients. Acta Chir Scand 151:685–693.

    Google Scholar 

  58. Moertel CG, Childs DS, Reitemeier RJ, et al 1969;Combined 5‐fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal carcinoma. Lancet 2:865–867.

    Article  CAS  Google Scholar 

  59. Overgaard M, Berthelsen K, Dahlmark M, et al. A randomized trial of radiotherapy alone or combined with 5‐FU in the treatment of locally advanced colorectal carcinoma. ECCO 5, meeting abstract 1989:0‐0626.

    Google Scholar 

  60. Wassif‐Boulis S. 1982;The role of preoperative adjuvant therapy in management of borderline operability of rectal cancer. Clin Radiol 33:353–358.

    Article  Google Scholar 

  61. Frykholm GJ, Pahlman L, Glimelius B. 2001;Combined chemo and radiotherapy versus radiotherapy alone in the treatment of primary, non‐resectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 50:433–440.

    Article  Google Scholar 

  62. Janjan NA, Abbruzzese J, Pazdur R, et al 1999;Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. Radiother Oncol 51: 153–160.

    Article  CAS  Google Scholar 

  63. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. 2002;Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94: 1121–1130.

    Article  Google Scholar 

  64. Glynne‐Jones R, Sebag‐Montefiore D. 2002;Chemoradiation schedules—what radiotherapy? Eur J Cancer 38:258–269.

    Article  Google Scholar 

  65. Valentini V, Coco C, Cellini N, et al 1999;Preoperative chemoradiation with cisplatin and 5‐fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 45:1175–1184.

    Article  CAS  Google Scholar 

  66. Grann A, Minsky BD, Cohen AM, et al 1997;Preliminary results of preoperative 5‐fluorouracil, low‐dose leucovorin and concurrent radiation therapy for clinically respectable T3 rectal cancer. Dis Colon Rectum 40:515–522.

    Article  CAS  Google Scholar 

  67. Hyams DM, Mamounas EP, Petrelli N, et al 1997;A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R‐03. Dis Colon Rectum 40:131–139.

    Article  CAS  Google Scholar 

  68. Rouanet P, Saint‐Aubert B, Lemanski C, et al 2002;Restorative and nonrestorative surgery for low rectal cancer after high‐dose radiation. Dis Colon Rectum 45:305–315.

    Article  Google Scholar 

  69. Mohiuddin M, Regine WF, Marks GJ, Marks JW. 1998;High dose preoperative radiation and the challenge of sphincter‐preservation surgery for rectal cancer of the distal 2 cm of the rectum. Int J Radiat Oncol Biol Phys 40:569–574.

    Article  CAS  Google Scholar 

  70. Habr‐Gama A, de Souza PM, Ribeiro U, et al 1998;Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 41:1087–1096.

    Article  Google Scholar 

  71. Moore HG, Riedel E, Minsky BD, et al 2003;Adequacy of 1 cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined‐modality therapy. Ann Surg Oncol 1:80–85.

    Article  Google Scholar 

  72. Karnjia ND, Schache DJ, Nort WR, Heald RJ. 1990;‘Close shave’ in anterior resection. Br J Surg 63:673–677.

    Google Scholar 

  73. Francois Y, Nemoz CJ, Baulieux J, et al 1999; Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter‐sparing surgery for rectal cancer: the Lyon R90‐01 randomized trial. J Clin Oncol 17:2396–2402.

    CAS  PubMed  Google Scholar 

  74. Bujko K, Nowacki MP, Bebenek M, et al 2004;Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short‐term radiotherapy versus conventionally fractionated radiochemotherapy. Radiother Oncol 72(1):15–24.

    Article  CAS  Google Scholar 

  75. Frigell A, Ottander M, Stenbeck H, Påhlman L. 1990;Quality of life of patients treated with abdominoperineal resection or anterior resection for rectal carcinoma. Ann Chir Gynaecol 79: 26–30.

    CAS  Google Scholar 

  76. Taal BG, Van Tinteren H, Zoetmulder FA, et al 2001;Adjuvant 5‐FU plus levamisole in colonic or rectal cancer: improved survival in stage II or III. Br J Cancer 85:1437–1443.

    Article  CAS  Google Scholar 

  77. Glimelius B, Cedermark B, Dahl O, et al. Adjuvant chemotherapy in colorectal cancer: joint analyses of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer, ECCO 12, abstract‐book 2003;39(suppl 1):S318. Abstr 1066.

    Google Scholar 

Download references

Authors
  1. Judith L. Trudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lars A. Påhlman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Professor of Surgery, Mayo Clinic College of Medicine, Chairman, Division of Colon and Rectal Surgery, Mayo Clinic Foundation, Rochester, MN, USA

    Bruce G. Wolff MD, FASCRS (Senior Editors) (Senior Editors)

  2. Professor of Surgery, Chief, Section of Colorectal Surgery, Washington University School of Medicine, St. Louis, MO, USA

    James W. Fleshman MD, FASCRS (Senior Editors) (Senior Editors)

  3. Chairman, Department of Colon and Rectal Surgery, Ochsner Clinic Foundation, New Orleans, LA, USA

    David E. Beck MD, FASCRS (Senior Editors) (Senior Editors)

  4. Professor of Surgery, Mayo Clinic College of Medicine, Consultant, Colon and Rectal Surgery, Mayo Clinic and Mayo Foundation, Rochester, MN, USA

    John H. Pemberton MD, FASCRS (Senior Editors) (Senior Editors)

  5. Chief of Staff, Cleveland Clinic Florida, Weston, FL, USA

    Steven D. Wexner MD, FASCRS (Senior Editors) (Senior Editors)

  6. Victor W. Fazio Chair of Colorectal Surgery, Department of Colorectal Surgery, Cleveland Clinic Foundation, Cleveland, OH, USA

    James M. Church BSc, MBChB, MMed Sci, FASCRS (Associate Editors) (Associate Editors)

  7. Professor of Surgery, Chief, Section of Colon and Rectal Surgery, Department of Surgery, University of California, San Francisco, San Francisco, CA, USA

    Julio Garcia-Aguilar MD, PhD, FASCRS (Associate Editors) (Associate Editors)

  8. Department of Colon and Rectal Surgery, Lahey Clinic, Burlington, MA, USA

    Patricia L. Roberts MD, FASCRS (Associate Editors) (Associate Editors)

  9. Professor of Surgery, Head, Section of Colon and Rectal Surgery, Rush University Medical Center, Chicago, IL, USA

    Theodore J. Saclarides MD, FASCRS (Associate Editors) (Associate Editors)

  10. Division of Colon and Rectal Surgery, Department of Surgery, University of California, Irvine Medical Center, Orange, CA, USA

    Michael J. Stamos MD, FASCRS (Associate Editors) (Associate Editors)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this entry

Cite this entry

Trudel, J.L., Påhlman, L.A. (2007). Adjuvant Therapy for Colorectal Cancer. In: Wolff, B.G., et al. The ASCRS Textbook of Colon and Rectal Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-36374-5_31

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-36374-5_31

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24846-2

  • Online ISBN: 978-0-387-36374-5

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation